適用於直腸癌的 IMMUNOSCORE®

適用於直腸癌的 IMMUNOSCORE® 有助於鑑別復發風險較低，亦是接受器官保留治療的良好人選的局部進展期直腸癌 (LARC) 病患。可於公司進行臨床驗證研究時，透過「創新准入計劃」使用 IMMUNOSCORE®。

featured-image
專業臨床中心現在可透過「創新准入計劃」使用適用於直腸癌的 IMMUNOSCORE®

閱讀

如何訂購
Immunoscore Rectal Word Logo RGB

適用於醫療照護專業人員

適用於病患

利用 IMMUNOSCORE® 預測復發風險：評估直腸癌預後

illus_Patient_IC_Risk-Of-Relapse-brochure-HCP-rectal-1_CN

IMMUNOSCORE® 可透過精準測量 T 淋巴球的腫瘤浸潤，使醫療照護提供者了解復發的風險。

IMMUNOSCORE® Low 或 Intermediate 代表存在少量 T 細胞對抗癌症，這表示復發風險較高。反之，IMMUNOSCORE® High 代表 T 淋巴球高度浸潤，表示復發風險較低。

illus_Patient_IC_Risk-Of-Relapse-brochure-HCP-rectal-1_CN

臨床獲益

利用適用於直腸癌的 IMMUNOSCORE®，協助醫師鑑別非手術治療（Watch and Wait，觀察等待）的人選

LARC 病患的治療方式正在發生轉變 [1,2]。對術前輔助性治療 (NT) 表現出臨床完全緩解 (cCR) 的病患或許能夠避免全直腸繫膜切除術 (TME)，該手術會導致病患生活品質降低 [3]。

但是，在缺乏預測癌症復發風險的可靠生物標誌物的情況下，難以鑑別適合接受非手術治療（觀察等待）的病患。

一項新的研究 [4] 表明，IMMUNOSCORE® 結合成像可鑑別對 NT 有絕佳反應的病患，這些病患能從器官保留策略中獲益。在「觀察等待」組別中，觀察到 IMMUNOSCORE High 的病患 100% 獲得成功。

IMMUNOSCORE® 預測 LARC 病患的臨床結果 [4]

IMMUNOSCORE High 的病患臨床結果良好（5 年無病存活率：89% vs 63% vs 55%）。

DFS__2_-removebg_CN

接受 CRT 和根治性手術的 LARC 病患 (n=238)。

TTR__1_-removebg_CN

化療後完全臨床緩解的 LARC 病患 (n=73)。

IMMUNOSCORE® 選擇符合「觀察等待」方法條件的 LARC 病患。[4]

臨床完全緩解且 IMMUNOSCORE High 的病患不會復發，且有可能符合器官保留的條件。

依據 IMMUNOSCORE 而接受 CRT 和根治性手術的病患之 5 年無病存活率 [4]：

89%

IMMUNOSCORE High 者

63%

IMMUNOSCORE Intermediate 者

55%

IMMUNOSCORE Low 者

常見問題

查看所有常見問題

Immunoscore® 是以組織進行的免疫試驗，可測量宿主在腫瘤部位的免疫反應。此試驗是在局部大腸癌的切除組織，製成的福馬林固定石蠟包埋 (FFPE) 腫瘤組織檢體上進行。試驗中使用全切片成像和人工智慧演算法，評估 FFPE 腫瘤切片中 T 細胞的類型、密度和位置，以判定每位患者的個別 Immunoscore®。

對於局部大腸癌，Immunoscore® 結果結合標準臨床病理學特徵，能夠協助判定復發風險，並調整早期大腸癌患者的輔助化療決策。

我們的實驗室收到樣本後，將在 10 個工作日內向您提供結果。

「創新准入計劃讓我們有機會將 IMMUNOSCORE® 納入病患「觀察等待」方法資格的評估。這將讓我們對病患照護更有信心，並個人化治療計畫。」

JOHN LOW SENG HOOI. 醫生，馬來西亞吉隆坡泛泰醫院臨床腫瘤科

醫師

有興趣訂購檢測嗎？

選擇您的國家/地區

IMMUNOSCORE® for the management of locally advanced rectal cancer (LARC) is available in select locations through an Innovation Access Program (IAP). Find out if you can participate in the IAP by emailing us at infos@haliodx.com or fill in the contact form below.

Contact us for details as the test is not available in the US

veracyte-logo-v-min

Veracyte

Luminy Biotech Entreprises
163 Avenue de Luminy
13288 Marseille Cedex 9
FRANCE

phone-solide

Phone No : +33 (0) 4 91 29 30 90

Contact Form




    您提供了電子郵件資訊，關於我們的產品和服務，我們將用這些資訊聯絡您。這些資訊不會出售給任何第三方。Veracyte SAS 只會為了資料託管、行銷活動而將您的個人資訊移轉至我們的 CRM 系統，以及為了商業活動而將您的個人資料移轉給我們的經銷商合作夥伴。

    您可以隨時發送電子郵件至 privacy@haliodx.com.您可以隨時發送電子郵件至 privacy@haliodx.com 取消訂閱。有關我們的隱私實踐和隱私保護承諾的資訊，請查看 隱私政策。隱私政策.

    我們的方案

    用於直腸癌的 IMMUNOSCORE® 可通過我們的訪問計劃在美國境外使用。請填寫上面的聯繫表格與我們聯繫以了解更多信息。

    Step 1: Obtain specimen collection kits

    If you qualify for participation in the IAP, you will be given information on how to order a specimen collection kit. Please be sure to include the address for the laboratory where the patient’s specimen is stored so we can send the kit to the correct location.

    step_1_img@2x

    Step 2: Complete all documents provided within the collection kit

    Please be sure to supply all of the requested information on the forms that are included in the specimen collection kit.

    Please be sure to supply all of the requested information on the forms that are included in the specimen collection kit.

    You can also download the necessary information using the link below:

    TEST REQUEST FORM

    step2

    Step 3: Prepare and send the patient sample

    Veracyte can work directly with the pathology team and treating physician to facilitate specimen collection.

    The tissue specimen should be from tumor biopsy at diagnosis of patients with LARC and not from a site of metastasis. You can send either an FFPE tumor block or 4 µm unstained slides from an FFPE block (6 slides required per test).

    To prepare the patient specimen, follow the instructions in the Samples Preparation Instructions included in the kit.

    Once the sample is prepared and placed in the specimen collection kit along with the required documentation, return the kit to Veracyte.

    HalioDx can work directly with the pathology team and treating physician to facilitate specimen collection.

    The tissue specimen should be from tumor biopsy at diagnosis of patients with LARC and not from a site of metastasis. You can send either an FFPE tumor block or 4 µm unstained slides from an FFPE block (6 slides required per test).

    To prepare the patient specimen, follow the instructions in the following downloadable document:

    Samples preprations instructions

    Once the sample is prepared and placed in the specimen collection kit along with the required documentation, return the kit to HalioDx.

    shipment-@2x

    Step 4: Access your IMMUNOSCORE Results

    The turnaround time for Immunoscore® testing is a maximum of 10 working days. Turnaround time is considered from the day the specimen is received at our laboratory to the time the test is reported to the ordering physician.

    You will receive the Immunoscore® results by email.

    您也可以直接登錄腫瘤學門戶獲取結果。

    step4

    Step 1: Obtain specimen collection kits

    If you qualify for participation in the IAP, you will be given information on how to order a specimen collection kit. Please be sure to include the address for the laboratory where the patient’s specimen is stored so we can send the kit to the correct location.

    step_1_img@2x

    Step 2: Complete all documents provided within the collection kit

    Please be sure to supply all of the requested information on the forms that are included in the specimen collection kit.

    You can also download the necessary information using the link below:

    step2

    Step 3: Prepare and send the patient sample

    Veracyte can work directly with the pathology team and treating physician to facilitate specimen collection.

    The tissue specimen should be from tumor biopsy at diagnosis of patients with LARC and not from a site of metastasis. You can send either an FFPE tumor block or 4 µm unstained slides from an FFPE block (6 slides required per test).

    To prepare the patient specimen, follow the instructions in the following downloadable document:

    Samples Preparation Instructions
    Once the sample is prepared and placed in the specimen collection kit along with the required documentation, return the kit to Veracyte.

    HalioDx can work directly with the pathology team and treating physician to facilitate specimen collection.

    The tissue specimen should be from tumor biopsy at diagnosis of patients with LARC and not from a site of metastasis. You can send either an FFPE tumor block or 4 µm unstained slides from an FFPE block (6 slides required per test).

    To prepare the patient specimen, follow the instructions in the Samples Preparation Instructions included in the kit.

    Once the sample is prepared and placed in the specimen collection kit along with the required documentation, return the kit to HalioDx.

    shipment-@2x

    Step 4: Access your IMMUNOSCORE Results

    The turnaround time for Immunoscore® testing is a maximum of 10 working days. Turnaround time is considered from the day the specimen is received at our laboratory to the time the test is reported to the ordering physician.

    You will receive the Immunoscore® results by email.

    您也可以直接登錄腫瘤學門戶獲取結果。

    step4

    醫療照護專業人員的首要資源

    查看所有資源
    resources-publications (2)
    診斷活檢適應的免疫評分預測對新輔助治療的反應

    查看出版物

    thumb
    直腸癌免疫評分手冊

    下載

    聯繫我們的團隊，洽詢 IMMUNOSCORE

    聯絡我們

    經銷商和商業團隊區域

    登入

    引用資料

    1. Hill GL and Rafique M. Extrafascial excision of the rectum for rectal cancer. Br J Surg. 1998 Jun;85(6):809-12.
    2. Bjerkeset T and Edna TH. Rectal cancer: the influence of type of operation on local recurrence and survival. Eur J Surg. 1996 Aug;162(8):643-8.
    3. Pieniowski EHA, et al. Prevalence of low anterior resection syndrome and impact on quality of life after rectal cancer surgery: population-based study. BJS Open. 2020 Oct;4(5):935-942.
    4. El Sissy C, et al. A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy. Clin Cancer Res. 2020 Oct 1;26(19):5198-5207.
    5. Anitei M-G, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res. 2014 Apr 1;20(7):1891-9.